Physician profile
Bruce Bennin
NPI 1902915507
$14,270.73
in general payments reported to CMS, 2019-2025
35 companies · $3,195 in 2025
The $3,195 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,636 · 2020: $260 · 2021: $505 · 2022: $1,074 · 2023: $3,503 · 2024: $4,097 · 2025: $3,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,958 · Food and Beverage: $4,823 · Education: $14.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,958.04 |
| Food and Beverage | $4,822.58 |
| Education | $14.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,581.66 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $997.25 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $850.86 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $545.46 | 2019-2025 | |
| Pfizer INC. | $496.36 | 2019-2025 | |
| Dermavant Sciences, INC. | $452.08 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $425.67 | 2019-2025 | Tremfya |
| Amgen INC. | $388.46 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $307.81 | 2019-2025 | Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $284.61 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $275.63 | 2019-2025 | Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $248.09 | 2022-2024 | Sotyktu |
| Incyte Corporation | $224.46 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $221.51 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $193.23 | 2019-2025 | Bimzelx |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $106.79 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $89.80 | 2023-2025 | Zoryve |
| Biofrontera INC. | $77.78 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $70.62 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $51.23 | 2019-2023 | |
| Epi Health, LLC | $43.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.47 | 2023-2024 | Spevigo |
| Sandoz INC. | $40.56 | 2019 | |
| Almirall LLC | $31.70 | 2019 | |
| Merck Sharp & Dohme LLC | $26.88 | 2019 | |
| Verrica Pharmaceuticals INC. | $25.35 | 2024 | Ycanth |
| Botanix Sb INC | $24.01 | 2025 | Sofdra |
| Organogenesis INC. | $23.06 | 2023 | Puraply |
| Blueprint Medicines Corporation | $22.02 | 2024 | Ayvakit |
| Dermira, INC. | $19.45 | 2019 | |
| Strata Skin Sciences, INC. | $19.41 | 2024 | Xtrac |
| Fresenius Kabi USA, LLC | $17.98 | 2023 | |
| Journey Medical Corporation | $16.84 | 2023 | |
| Celgene Corporation | $16.75 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Bennin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.